Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cardiovascular Screening in Infants Born Small for Gestational Age (CardioSGA)

28 november 2018 uppdaterad av: Flavia Prodam, Azienda Ospedaliero Universitaria Maggiore della Carita

Cardiovascular Screening in 2-year Old Infants Born Small for Gestational Age Compared With Infants Born Adequate for Gestational Age

Aims of this study were 1) to evaluate early CV abnormalities in infants born small for gestational age (SGA) at 24 months of age compared with age and sex-matched subjects that were born adequate for gestational age (AGA) 2) to investigate the effect of catch-up growth and the role of breastfeeding on CV risk.

Studieöversikt

Detaljerad beskrivning

We consecutively enrolled 20 SGA infants, born at term (37+0/41+3 week gestation), aged 24 months, and 20 AGA, age- and sex-matched controls. SGA was defined as a birth weight <10th percentile for sex, gestational age and birth order, and AGA as a birth weight between the 10th and the 90th percentile, according to Italian neonatal anthropometric charts.

Clinical and anthropometric variables The infants' prenatal and neonatal data were retrospectively recorded, namely a history of gestational diabetes and hypertension, the presence of intrauterine growth restriction, maternal weight gain during pregnancy, Apgar score, gestational age and birth weight, length, and head circumference. All subjects' parents completed a questionnaire including family history, maternal smoking during pregnancy, breastfeeding duration. At the time of enrollment (24 months), anthropometric data were evaluated by trained physicians according to standard procedures and based on the WHO growth charts. Height, weight, systolic (SBP) and diastolic (DBP) blood pressure were measured. Body mass index (BMI) was calculated as weight (kg)/height(cm)2 and weight gain in the first 2 years of life was calculated as the delta between birth weight and weight at 24 months.

Echocardiographic assessment Transthoracic echocardiogram using a Vivid 7 Pro ultrasound scanner (General Electric Healthcare, USA) was performed by an expert pediatric cardiologist, blinded to patients' clinical data. Measurements of left ventricle (LV end-diastolic diameter, LVEDD; LV end-systolic diameter, LVESD; interventricular septum at end diastole, IVSD; LV posterior wall at end diastole, LVPWD), relative wall thickness (RWT), left atrium diameter (LAD), the maximum LA volume, LV ejection fraction, and tricuspid annular plane systolic excursion (TAPSE) were obtained according to established standards. LV mass (LVM) was derived from the Devereux formula and indexed to body surface area (left ventricular mass index, LVMI). Left ventricular output (LVO) was obtained with the velocity time integral (VTI) from a 5-chamber view and calculated as follows LVO=[(VTI)x(heart rate)x(cross-sectional area)] and indexed to body weight.

Using pulsed wave Doppler, mitral inflow velocities, peak early diastolic velocity (E), peak late diastolic velocity (A), and E/A ratio, were measured. Pulsed wave tissue Doppler of the lateral mitral annulus was used for the measurement of early peak diastolic mitral annular velocity (E'). The E/E' ratio was calculated. End-diastolic pressure (EDP) was calculated from the E/E' ratio with the formula EDP=1.91+1.24xE/E' (14) and the pressure-volume curve during diastole with the formula EDP = αxEDVβ (end-diastolic volume, EDV). Volume parameters were corrected to fixed values of EDP (V30 mmHg). The coefficient "β" (Beta), indicating the slope of the end-diastolic pressure-volume relationship (EDPVR), was calculated with the formula β=[Log10(EDP/30)]/[Log10(EDV/V30mmHg)].

Vascular assessment Vascular measurements were performed with a high-resolution ultrasonography (Esaote MyLab25TM Gold, Esaote, Italy) using a 8 mHz linear transducer and a 5 mHz convex transducer for the abdominal aorta, by an expert vascular surgeon blinded to patients' clinical status. CIMT, abdominal aortic diameter at maximum systolic expansion (Ds) and minimum diastolic expansion (Dd), brachial artery diameters, brachial artery peak systolic velocity (PSV) and end diastolic velocity (EDV) were measured as previously described and aortic strain (S), pressure strain elastic modulus (Ep), pressure strain normalized by diastolic pressure (Ep*) and brachial artery flow-mediated dilation (FMD) were calculated. While S is the mean strain of the aortic wall, Ep and Ep* are the mean stiffness (16). Arterial wall stiffness index (β index) was calculated with the formula: β index=ln(SBP/DBP)/[(Ds-Dd) /Dd)] (17) and systemic vascular resistance (dynes/s/cm2) with the formula: SVR=(mean BP- right atrial pressure)/LVO, with an estimated right atrial pressure of 5 mmHg. The brachial artery maximum diameter recorded following reactive hyperemia was reported as a percentage change of resting diameter (FMD = peak diameter - baseline diameter/baseline diameter).

Studietyp

Observationell

Inskrivning (Faktisk)

40

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Novara, Italien, 28100
        • AOU Maggiore della Carità - Clinica Pediatrica - Ambulatorio di Auxologia ed Endocrinologia Pediatrica

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

2 år till 2 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

We consecutively enrolled 20 SGA infants, born at term (37+0-41+3 weeks gestation), aged 24 months, and 20 AGA, age- and sex-matched controls. SGA was defined as a birth weight <10th percentile for sex, gestational age and birth order, and AGA as a birth weight between the 10th and the 90th percentile, according to Italian neonatal anthropometric charts

Beskrivning

Inclusion Criteria:

  • infants, 24-month old, born at term SGA or AGA

Exclusion Criteria:

  • heart, respiratory, liver and kidney diseases, congenital malformations, genetic diseases, neonatal asphyxia, parenteral nutrition, congenital inborn errors of metabolism, and preterm and twin birth.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
SGA vs AGA infants
infants, born at term (37+0/41+3 week gestation), aged 24 months, with a birth weight <10th percentile or between 10th and 90th percentile for sex, gestational age, and birth order, according to Italian neonatal anthropometric charts

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Cardiovascular structure
Tidsram: 24 months
Heart structure
24 months
Cardiovascular function
Tidsram: 24 months
Heart function
24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
catch-up growth
Tidsram: 24 months
delta between body weight at 24 months and birth weight
24 months
breastfeeding duration
Tidsram: 24 months
breastfeeding duration
24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 september 2017

Primärt slutförande (Faktisk)

1 mars 2018

Avslutad studie (Faktisk)

1 juli 2018

Studieregistreringsdatum

Först inskickad

27 november 2018

Först inskickad som uppfyllde QC-kriterierna

28 november 2018

Första postat (Faktisk)

29 november 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 november 2018

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 november 2018

Senast verifierad

1 november 2018

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • CE 106/18

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera